Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	108 people 2 RCTs in this analysis	Extrapyramidal symptoms with risperidone with first-generation antipsychotic drugs Absolute results not reported	RR 0.47 95% CI 0.22 to 0.99	Small effect size	risperidone
Systematic review	108 people 2 RCTs in this analysis	Sedation with risperidone with first-generation antipsychotic drugs Absolute results not reported	RR 2.59 95% CI 0.29 to 22.94		Not significant
Systematic review	2243 people 11 RCTs in this analysis	Proportion of people who withdrew because of adverse effects 142/1619 (9%) with risperidone 70/624 (11%) with first-generation antipsychotic drugs	RR 0.82 95% CI 0.61 to 1.09		Not significant
Systematic review	2738 people 10 RCTs in this analysis	Extrapyramidal symptoms 384/1937 (20%) with risperidone 289/765 (38%) with first-generation antipsychotic drugs	RR 0.63 95% CI 0.56 to 0.71	Small effect size	risperidone
Systematic review	2524 people 11 RCTs in this analysis	Antiparkinsonian medication 461/1856 (25%) with risperidone 289/668 (43%) with first-generation antipsychotic drugs	RR 0.66 95% CI 0.58 to 0.74	Small effect size	risperidone
Systematic review	1708 people 4 RCTs in this analysis	Weight gain 420/1320 (32%) with risperidone 71/388 (18%) with first-generation antipsychotic drugs	RR 1.55 95% CI 1.25 to 1.93	Moderate effect size	first-generation antipsychotic drugs